CAR-T– tag –

Structural comparison of CAR-T's three commercialization paths (autologous, allogeneic, in vivo) across 7 axes. Market projection: $16.5B in 2030, $35B in 2035, with in vivo's late-decade growth. Final volume.

Comparing 5 in vivo CAR-T companies (Capstan, Umoja, Orna, Renagade, Sana) on technology platform (LNP-mRNA, LV, circular RNA, multi-organ LNP), indication focus (autoimmune vs cancer), strategic partners (Pfizer, Lilly, Merck). Vol. 2.

April 21, 2026 Eli Lilly to acquire Kelonia Therapeutics for up to $7B—the largest in vivo CAR-T M&A signaling pharma majors' serious entry. Kelonia's PreciseTarget LNP delivers CAR mRNA to T cells in vivo, softening ex vivo CAR-T's three walls (manufacturing time, cost, toxicity) simultaneously. Vol. 1.

[Regulatory Update] FDA Removes REMS Requirements for Approved CAR-T Therapies In June 2025, the U.S. Food and Drug Administration (FDA) officially eliminated Risk Evaluation and Mitigation Strategies (REMS) requirements for autologous c...

Strategic Review: Shifting from Antivirals to Oncology and Cell Therapy Gilead Sciences, once dominant in the antiviral space—particularly in HIV and hepatitis C—has been facing declining revenue due to patent cliffs. Gilead Sciences, on...

While CAR T cell therapies have shown success primarily in hematologic malignancies, new advances are emerging for gastrointestinal (GI) solid tumors such as colorectal, gastric, and esophageal cancers. U.S. research teams have reported ...